Characteristics and clinical outcomes of study cohort of patients with pancreatic cancer
| Variable . | n (% missing values) . | Median [IQR] or count (%) . |
|---|---|---|
| Baseline characteristics | ||
| Age, y | 139 (0) | 65.8 [58.3-73.4] |
| Female | 139 (0) | 78 (56.1) |
| BMI, kg/m2 | 138 (0.7) | 23.0 [20.6-33.7] |
| KPS | 64 (54) | 80 [70-90] |
| History of VTE* | 139 (0) | 5 (3.6) |
| Stage of disease | 134 (0.4) | |
| Locally advanced | 53 (39.6) | |
| Distant metastatic | 81 (60.4) | |
| Baseline PAI-1 levels | 139 (0) | 3.3 [1.4-10.3] |
| Clinical outcomes | ||
| Death within 2 y | 139 (0) | 98 (70.5) |
| Median overall survival | 11.2 mo; 95% CI, 8.9-14.7 | |
| VTE within 2 y | 139 (0) | 25 |
| Cumulative incidence at 6 mo | 12.7%; 95% CI, 7.7-19.0 | |
| Cumulative incidence at 12 mo | 15.0%; 95% CI, 9.6-21.6 | |
| Cumulative incidence at 24 mo | 19.0%; 95% CI, 12.8-26.1 | |
| Variable . | n (% missing values) . | Median [IQR] or count (%) . |
|---|---|---|
| Baseline characteristics | ||
| Age, y | 139 (0) | 65.8 [58.3-73.4] |
| Female | 139 (0) | 78 (56.1) |
| BMI, kg/m2 | 138 (0.7) | 23.0 [20.6-33.7] |
| KPS | 64 (54) | 80 [70-90] |
| History of VTE* | 139 (0) | 5 (3.6) |
| Stage of disease | 134 (0.4) | |
| Locally advanced | 53 (39.6) | |
| Distant metastatic | 81 (60.4) | |
| Baseline PAI-1 levels | 139 (0) | 3.3 [1.4-10.3] |
| Clinical outcomes | ||
| Death within 2 y | 139 (0) | 98 (70.5) |
| Median overall survival | 11.2 mo; 95% CI, 8.9-14.7 | |
| VTE within 2 y | 139 (0) | 25 |
| Cumulative incidence at 6 mo | 12.7%; 95% CI, 7.7-19.0 | |
| Cumulative incidence at 12 mo | 15.0%; 95% CI, 9.6-21.6 | |
| Cumulative incidence at 24 mo | 19.0%; 95% CI, 12.8-26.1 | |
BMI, body mass index; IQR, interquartile range; KPS, Karnofsky Performance Scale.
Patients with prior VTE were only eligible if event was ≥3 months before inclusion according to the inclusion criteria for the Vienna Cancer and Thrombosis Study.